Bingfeng Liu

机构：Harbin Institute of Technology, Joint Research Center · ORCID：0000-0003-1278-727X

发表论文 68 篇 · 总被引 2978 次 · h-index 27

代表论文

• Enhancement of CAR‐T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins (2023 · 癌症：英文版 · 被引 50)
• A Mosaic Nanoparticle Vaccine Elicits Potent Mucosal Immune Response with Significant Cross‐Protection Activity against Multiple SARS‐CoV‐2 Sublineages (2023 · Advanced Science · 被引 35)
• Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment (2023 · Molecular Therapy — Oncolytics · 被引 35)
• Development of a PCSK9-targeted nanoparticle vaccine to effectively decrease the hypercholesterolemia (2024 · Cell Reports Medicine · 被引 25)
• The construction of modular universal chimeric antigen receptor T (MU-CAR-T) cells by covalent linkage of allogeneic T cells and various antibody fragments (2024 · Molecular Cancer · 被引 23)
• The receptor binding domain of SARS-CoV-2 Omicron subvariants targets Siglec-9 to decrease its immunogenicity by preventing macrophage phagocytosis (2024 · Nature Immunology · 被引 18)